Bill Rhodes is Founding Member of Third Day Advisors LLC, a management and strategy advisory firm specializing in helping healthcare and life sciences companies as they consider corporate mergers and acquisitions as part of their growth plans. He is also an Operating Partner with Linden Capital Partners LP, a Chicago-based healthcare private equity firm, where he is responsible for the life sciences and diagnostics sector.
Prior, Mr. Rhodes was with Becton Dickinson and Co. (BD), a Fortune 500, multi-national healthcare products corporation, as a named Executive Officer and the Senior Vice President, Business Development and Strategy. He was responsible for corporate strategy and global M&A activities.
Previous to this role, he served as BD’s Worldwide President, BD Biosciences, a 3,000 person, US $1.4 billion segment, responsible for its three business units: Cell Analysis, Discovery Labware and Advanced Bioprocessing. Prior to assuming that role, he was President, Cell Analysis, and before that, VP of Business Development and Strategic Investments, where he held worldwide responsibility for business development activities. He also formed and managed BD Ventures L.L.C., the corporate venture capital fund operated by BD.
Prior to joining BD, Mr. Rhodes held various senior executive roles in business development and technology, for Pfizer, Johnson and Johnson and The William James Company.
Mr. Rhodes also currently serves as Senior Executive in Residence at Cornell University, where he identifies university-based technologies appropriate for business formation, and mentors entrepreneurs. In addition, he is a Clinical Instructor with the Weill Cornell Medical College’s Department of Public Health.
John Wallace is a results-oriented senior executive with over 30 years of global experience in management, operations, finance, international business and manufacturing. He has a diverse background and a proven track record of strong leadership.
Mr. Wallace was the Chief Operating Officer at Nova Biomedical Corporation, a world leader in the development, marketing and manufacture of proprietary blood diagnostic products, consumer healthcare diabetes products and medical devices for Fortune 500 and emerging companies. Nova is a pioneer in the development of biosensors for whole blood diagnostics to support the care of critically ill patients. With more than $175 million in revenue run rate and in excess of $35 million in operating profits, Nova was built by the strength and depth of its 750+ employees and sweat equity. Mr. Wallace led the management of strategic alliances and served on the Board of Directors, the Corporate Quality Committee and was the Chairman of the Operating Committee. Nova experienced consistent record revenue and earnings growth during his tenure.
Mr. Wallace has served on numerous Boards including on the Board of Directors and as Chairman of the Audit Committee of Zoll Medical Inc. (NASDAQ), a world leader in resuscitation and critical care devices. The Company experienced rapid market expansion and numerous product innovations during his involvement with Zoll. Mr. Wallace played an active role in the acquisition of Zoll by Japan’s Asahi Kasei Corporation in a $2.2 billion cash transaction where Zoll’s management and employees remained intact.
Earlier in his career, Mr. Wallace was a senior executive at Cortex Corporation as well as Numerix Corporation, and also held management positions with Analog Devices Inc., Data General Corporation and Federated Department Stores (Filene’s Division).
Currently, Mr. Wallace holds Board positions with Triangle, Inc., Massachusetts Medical Device Industry Council (MassMedic), Discovering Justice/James D. St. Clair Federal Court Education Program, Neighborhood Association of the Back Bay and is a Senior Advisor to Tower Three Medical (an arm of Tower Three Partners – a Greenwich Connecticut-based private equity firm) in the role of Executive Vice President and Chief Operating Officer, where he provides guidance on evaluating potential acquisitions and financial/operational implementation and effectiveness.
Nate McLemore is a Managing Director for Columbia Pacific Management, where he is responsible for the firm’s healthcare investments with a primary focus on hospitals and senior housing in Asia. Mr. McLemore is a Board Member of Columbia Asia, a healthcare system with 23 hospitals and clinics in India, Indonesia, Malaysia, and Vietnam. He also serves on the Board of Remote Medical International , a medical and rescue services company specializing in providing care in remote areas. In China, Mr. McLemore is working to expand Kaijian Healthcare, the first foreign-owned operator of senior housing in the country, as well as pursuing several projects to build and operate hospitals.
Prior to joining Columbia Pacific, Mr. McLemore was a General Manager in Microsoft’s Health Solutions Group, where he was responsible for international sales, business development, M&A, professional services, policy and compliance. Mr. McLemore joined Microsoft from RelayHealth, where he served as Vice President of Business Development for this leader in online, doctor-patient communication, which was acquired by McKesson in 2006.
Earlier in his career, Mr. McLemore headed CFM’s federal lobbying practice, where he represented health care systems and technology companies before Congress and the Executive Branch. Mr. McLemore has a BA in Political Science from Willamette University and an MBA from the University of California at Berkeley’s Haas School of Business. He enjoys spending time with his wife and two young sons and is an avid skier, runner, boater, and an aspiring golfer.
Jack Krouskup has over 35 years of experience serving clients in a variety of industries. His primary focus over the past ten years was clients in the chemical manufacturing, healthcare and life sciences industries. Mr. Krouskup was previously partner-in-charge of Deloitte’s Northern California financial services practice where he served on Deloitte’s financial services advisory committee. He served as advisory partner on a number of large Northern California clients, and used his years of experience to support Deloitte teams and provide insights to client management and audit committees. Mr. Krouskup also helped lead an internal Deloitte integration team to effect an international merger of major accounting firms.
Mr. Krouskup has years of boardroom experience representing Deloitte with numerous global and highly complex organizations. Consequently, he has extensive corporate governance background and deep familiarity with board and audit committee best practices. Additionally, he has served numerous early stage companies in both financial services and life sciences including several IPO and merger transactions. He has broad experience in Securities and Exchange Commission (SEC) matters and other accounting and reporting requirements including initial public offerings, debt and equity registrations, responding to SEC comment letters and foreign statutory audit filings. Jack assisted several companies (including McKesson and Huntsman Corporations) in their initial year of compliance with internal controls related to financial reporting (Sarbanes 404).
Mr. Krouskup previously concentrated on financial services clients and served as a technical advisor to several financial services industry groups. He served as lead client service partner for the San Francisco Federal Home Loan Bank and also worked with Federal regulators on the liquidation/receivership audits of several failed institutions.
Mr. Krouskup’s extensive experience in the areas of mergers and acquisitions, including due diligence evaluations in financial services, healthcare and distribution sectors bring significant value Magnolia Medical Technologies.
Ben Elowitz is co-founder and CEO of Wetpaint, a technology and media company that specializes in building audiences from the social web. The company’s Wetpaint Entertainment news and celebrity website reaches 12 million unique users per month.
Prior to Wetpaint, Mr. Elowitz co-founded Blue Nile (NILE), the largest online retailer of luxury goods; oversaw the $150 million commercial products business for fitness equipment manufacturer Precor; and was also an early employee at Fatbrain.com (FATB), an e-commerce company that went public in 1998 and was sold to Barnes & Noble in 1999.
Mr. Elowitz is a recognized a thought leader on the subject of entrepreneurship and the media industry. He is the author of the Digital Quarters blog and the Media Success newsletter open to senior industry executives only. He has also been an angel investor in various companies such as BetFair (BET:LN), Minted, Cheezburger Networks, and JustFab (IB Holdings); and is a frequent conference speaker on media, social content, and entrepreneurship.
Dennis Capovilla is a Silicon Valley executive whose 25+ year career has included senior management positions at Fortune 100, microcap and startup companies where he has garnered recognition for his entrepreneurial insight and strategic acumen. Mr. Capovilla currently serves on numerous boards and is Executive Director at Powis Inc.
As President and CEO of Southwall Technologies, an innovative thin film technology company focused on energy efficiency products, Mr. Capovilla restructured and turned around this underperforming company. He revitalized R&D, expanded sales, drove M&A activities and took the company on NASDAQ. He ultimately executed the strategic exit with the successful sale to Solutia; multiplying shareholder value by 5x in a short period of time.
At Palm, Mr. Capovilla restructured the enterprise go-to-market strategy and created a medical vertical for mobile clinical trials. At Fatbrain, a pioneering e-commerce company, Mr. Capovilla oversaw explosive growth and played a key role in the company’s NASDAQ IPO. As President and CEO of Fatbrain, he was named Entrepreneur of the Year for Technology by the Silicon Valley Business Journal in 2000. He later achieved a successful exit for Fatbrain by engineering the sale of the company to Barnes & Noble.
Previous to this role, Mr. Capovilla served as Director of Apple’s Imaging Division where he led a $250M division and held numerous sales leadership positions with the Xerox Corporation.